ARS Pharma appoints Donn Casale as President effective June 1, 2026

ARS Pharmaceuticals, Inc.

Donn Casale, 53, most recently Chief Commercial Officer at Dynavax (acquired by Sanofi), joins as President.
Casale will receive an annual base salary of $575,000 and target annual discretionary bonus of 45% of base.
Stock option grant valued at ~$6M under 2020 Equity Incentive Plan; exercise price = grant date closing price.
Option vests 25% after one year, then monthly over 36 months; subject to continued employment.
He replaces Richard Lowenthal as President; Lowenthal remains CEO.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Donn Casale

President

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2026-06-01
Filed: May 13, 2026, 8:15 AM ET

appointed Donn Casale as the Company’s President effective as of the date he commences employment with the Company, which date is expected to be June 1, 2026.

Role change

Richard Lowenthal

President

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2026-06-01
Successor: Donn Casale
Filed: May 13, 2026, 8:15 AM ET

Mr. Lowenthal previously served as President.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Donn Casale was appointed as President at ARS Pharmaceuticals, Inc..

Action: appointed
Role: President

Exact text from the filing

appointed Donn Casale as the Company’s President effective as of the date he commences employment with the Company, which date is expected to be June 1, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Richard Lowenthal changed role as President at ARS Pharmaceuticals, Inc..

Role: President

Exact text from the filing

Mr. Lowenthal previously served as President.

View on SEC.gov

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-220671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.